Dr. Daniela Bota
Associate Dean of Clinical Research and Associate Professor of Neurology UC Irvine
- Orange CA
Dr. Daniela A. Bota is a UCI Health neuro-oncologist who specializes in the treatment of primary and metastatic brain tumors.
Media
Biography
Bota is co-director of the UCI Health Comprehensive Brain Tumor Program and is a lead investigator on several clinical trials, including novel treatments using brain tumor vaccines and the use of electrical fields to inhibit the growth of gliomas.
Areas of Expertise
Accomplishments
Physicians of Excellence, Orange County Medical Association
2017-2019
Southern California Rising Star™
2015
Neurology — SuperDoctors® edition of Los Angeles magazine
Ruth L. Kirschstein National Research Service Award
2006-2007
American Federation of Aging Research Glenn/AFAR Fellowship
2001
Education
University of Southern California
PhD
Molecular Biology
2003
Carol Davila University of Medicine and Pharmacy
MD
1997
Affiliations
- American Board of Psychiatry and Neurology
- Society of Neuro-Oncology
- American Society of Clinical Oncology
- American Academy of Neurology
Media Appearances
2 new vaccines may be first step toward curing brain cancer
StudyFinds online
2024-09-10
Researchers Robert Dillman and Daniela Bota from the University of California-Irvine explain that recent developments in vaccine technology are offering new possibilities for patients battling this disease. Two promising candidates, in particular, are capturing the attention of researchers and clinicians alike: SurVaxM and AV-GBM-1. These innovative approaches represent a significant step forward in the ongoing battle against glioblastoma. The findings are published in the journal Oncotarget.
Novel approaches to malignant brain tumor treatment aim to overcome familiar challenges
Healio online
2022-01-27
“Achieving effective treatment with minimal side effects is the biggest challenge in the field of malignant brain tumors right now,” Daniela A. Bota, MD, PhD, professor of neurology, vice dean for clinical research and medical director of the comprehensive brain tumor program at University of California, Irvine, told Healio.
A Cancer-Quashing Microbe Emerges from the Deep
Hakai Magazine online
2021-08-31
Daniela Bota, then a fellow in neuro-oncology at Duke University in North Carolina, attended the annual conference for the American Association for Cancer Research, where she listened to Nereus scientists present results from their multiple myeloma trial. Bota was searching for potential glioblastoma treatments, and marizomib intrigued her.
UCI Health Research Leads Fight Against COVID-19
Irvine Standard online
2020-08-20
“This was extremely timely,” says Dr. Daniela Bota, vice dean for clinical research and medical director of the CCR, which now has 75 principal investigators and 120 clinical researchers on staff. “When COVID-19 hit, we had some advantages.”
Trump brags that he’s helping patients access medical ‘miracles.’ He isn’t.
The Washington Post online
2019-11-15
The idea of letting people take a gamble like that has intuitive appeal. But almost a year and a half after the law’s enactment, scholars and reporters looking for evidence of its effectiveness have turned up only a small number of people who have used the law to obtain treatment. Matt Bellina, an amyotrophic lateral sclerosis (ALS) patient who campaigned for the law, has been receiving an experimental therapy still in clinical testing from BrainStorm, the New York-based company has confirmed. Daniela Bota, a neurologist at the University of California at Irvine, helped secure a nonapproved drug through Right to Try for a patient with aggressive brain cancer, she told STAT News (and confirmed to The Washington Post).
Research Grants
The Mechanisms of Chemotherapy Induced Cognitive Defects
National Institutes of Health (NIH)
2011-2012
Articles
Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons
MitochondrionNaomi Lomeli, Kaijun Di, Diana C Pearre, Tzu-Feng Chung, Daniela A Bota
2020
Primary brain tumor patients often experience neurological, cognitive, and depressive symptoms that profoundly affect quality of life. The DNA alkylating agent, temozolomide (TMZ), along with radiation therapy forms the standard of care for glioblastoma (GBM) – the most common and aggressive of all brain cancers. Numerous studies have reported that TMZ disrupts hippocampal neurogenesis and causes spatial learning deficits in rodents; however, the effect of TMZ on mature hippocampal neurons has not been addressed.
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Clinical Cancer ResearchDavid A Reardon, Annick Desjardins, James J Vredenburgh, Donald M O'Rourke, David D Tran, Karen L Fink, Louis B Nabors, Gordon Li, Daniela A Bota, Rimas V Lukas, Lynn S Ashby, J Paul Duic, Maciej M Mrugala, Scott Cruickshank, Laura Vitale, Yi He, Jennifer A Green, Michael J Yellin, Christopher D Turner, Tibor Keler, Thomas A Davis, John H Sampson
2020
Purpose: Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for patients with relapsed, EGFRvIII-positive glioblastoma.
A Novel Rat Ovarian Cancer Model Developed to Examine Chemotherapy-Related Cognitive Impairments
Gynecologic OncologyD. Pearre, N. Lomeli, D. Bota
2020
OBJECTIVES: To describe a novel method of developing an ovarian cancer intraperitoneal (IP) and subcutaneous (SC) xenograft model with the purpose of extrapolating chemotherapy-related cognitive impairments (CRCI) in tumor-bearing rats.
PDCT-17 (LTBK-11). PNOC007: H3.3K27M Specific Peptide Vaccine Combined With Poly-ICLC for the Treatment of Newly Diagnosed HLA-A2+ H3.3K27M Midline Gliomas
Neuro-OncologyTimothy Cloughesy, Kevin Petrecca, Tobias Walbert, Nicholas Butowski, Michael Salacz, James Perry, Denise Damek, Daniela Bota, Chetan Bettegowda, Jay-Jiguang Zhu, Fabio Iwamoto, Dimitris Placantonakis, Nina Martinez, J Bradley Elder, George Kaptain, David Cachia, Yaron Moshel, Steven Brem, David Picconi, Nam Tran, Do-Hyun Nam, Chul-Kee Park, Joseph Landolfi, David Tran, Rohan Ramakrishna, Karen Fink, Deborah Heros, Gelareh Zadeh, Garth Nicholas, Vivek Mehta, H Ian Robins, Clark Chen, Marshall Pitz, Jason Heth, Seema Nagpal, Michael Pearlman, Manmeet Ahluwalia, Nimish Mohile, Ryan Merrell, David Schiff, Reid Thompson, Raphael Davis, David Macdonald, Thian Kheoh, Fairooz Kabbinavar, Alexander Lossos, Michael Vogelbaum
2019
To assess within a multi-center trial the safety of H3.3K27M specific peptide vaccine in combination with poly-ICLC in HLA-A02.01+ patients diagnosed with H3.3K27M+ diffuse midline gliomas.
Management of low-grade glioma: a systematic review and meta-analysis
Neuro-Oncology PracticeTimothy J Brown, Daniela A Bota, Martin J van Den Bent, Paul D Brown, Elizabeth Maher, Dawit Aregawi, Linda M Liau, Jan C Buckner, Michael Weller, Mitchel S Berger, Michael Glantz
2018
Optimum management of low-grade gliomas remains controversial, and widespread practice variation exists. This evidence-based meta-analysis evaluates the association of extent of resection, radiation, and chemotherapy with mortality and progression-free survival at 2, 5, and 10 years in patients with low-grade glioma.
